Histone deacetylase (HDAC) inhibitors such as Trichostatin A to treat bronchoconstrictive diseases including asthma and chronic obstructive pulmonary disorder (COPD)
Asthma and COPD are diseases of variable airflow obstruction affecting more than 40 million Americans. Although some patients respond to conventional therapies, patients with severe disease disproportionately utilize healthcare resources. Therefore, new methods for treating asthma and COPD are needed.
Histone deacetylase (HDAC) inhibitors improve pulmonary function in animal models. The HDAC inhibitors, small molecules such as Trichostatin A, reverse the effects of drug-induced broncho-constriction by acting directly on pulmonary smooth muscle cells, a novel mechanism of action. The use of HDAC inhibitors alone, or in combination with known bronchodilators or corticosteroids, has therapeutic potential and offers increased therapeutic efficacy for the treatment of chronic obstructive pulmonary disorders.
Trichostatin A (TSA) che| HDAC Inhibitor
Small molecule therapeutic that dilates bronchi to treat asthma and other lung diseases
- Potential combination therapy
- Use for HDAC inhibitors for the treatment of broncho-constrictive disorders
Stage of Development:
Proof of concept in vivo
US 9,827,212 B2
Banerjee, A. et al.; AmJ Respir Cell Mol Biol 2012 Feb; 46(2): 132.
Docket # V4967